

**The Faculty of Medicine of Harvard University
Curriculum Vitae**

Date Prepared: July 12, 2022

Name: **Gabriela Soriano Hobbs, née Soriano**

Office Address: Massachusetts General Hospital Cancer Center
Zero Emerson Place, Suite 118, Room 138
Boston, MA 02114

Home Address: 60 Bridge Street, Needham, MA 02494

Work Phone: 617-724-1124

Work Email: ghobbs@mgh.harvard.edu

Work FAX: 617-724-1126

Place of Birth: Mexico City, Mexico

Education:

2004	BS (<i>Cum Laude</i>)	Biotechnology and Psychology	Tufts University
2008	MD	Medicine	Mount Sinai School of Medicine

Postdoctoral Training:

6/08-6/11	Resident	Internal Medicine	Brigham and Women's Hospital
7/11-6/14	Fellow	Hematology and Oncology	Memorial Sloan Kettering Cancer Center
7/11-6/14	Fellow	Hematology and Oncology	Weill Cornell Cancer Center

Faculty Academic Appointments:

8/14-	Instructor in Medicine	Medicine	Harvard Medical School
8/19-	Assistant Professor	Medicine	Harvard Medical School

Appointments at Hospitals/Affiliated Institutions:

8/14-	Assistant in Medicine	Leukemia Service	Massachusetts General Hospital
-------	-----------------------	------------------	--------------------------------

Major Administrative Leadership Positions:**Local**

10/16-	Clinical Director	Leukemia Service	Massachusetts General Hospital
--------	-------------------	------------------	--------------------------------

Committee Service:**Local**

2015	Hematology/Oncology Fellowship Clerkship Myeloid Leukemia Committee	Massachusetts General Hospital/ Dana-Farber Cancer Center
2016-	Intern Selection Committee	Brigham and Women's Hospital
2016-	Leukemia Faculty Recruitment Committee	Massachusetts General Hospital
2016 -	DF/HCC MPN Working Group	Massachusetts General Hospital, Dana-Farber/ Cancer Center
2017-	Oncology Service Line Inpatient Work Group	Massachusetts General Hospital
2017-	Oncology 2020 Steering Committee	Massachusetts General Hospital
2017-	URM Internal Medicine Intern Selection Sub Committee	Massachusetts General Hospital
2017-	<i>C. difficile</i> Coordinating Council	Massachusetts General Hospital
2018-	Inpatient Leadership Cabinet	Massachusetts General Hospital
2018-	Oncology Opiate Taskforce	Massachusetts General Hospital
2020-	Institutional Review Board	Massachusetts General Hospital
2020-	Faculty Development Anti-Racism Sub-Committee	Massachusetts General Hospital
2020-	Minority Recruitment Initiative Program Sub-Committee	American Society of Hematology

National

2014-	Chronic Myeloid Leukemia Committee	National Comprehensive Cancer Network
-------	------------------------------------	---------------------------------------

2015-	Myeloproliferative Neoplasm Committee	National Comprehensive Cancer Network
-------	---------------------------------------	---------------------------------------

Professional Societies:

2009-	American Society of Hematology	Associate Member
2012-	American Society of Clinical Oncology (ASCO)	Member
2012-	American Association of Cancer Research (AACR)	Member
2014	Society for Translational Oncology	

Grant Review Activities:

2020-present	ASH-HONORS Grant reviewer	American Society of Hematology, invited reviewer, Ad Hoc
2020	MPN Challenge Grant reviewer	MPN Research Foundation, inviter reviewer, Ad Hoc

Editorial Activities:

2019- 2021	JNCCN 360	CML Site Editor
2021	Blood Advances	Editorial Board

Ad hoc Reviewer:

Oncologist
 Biology of Blood and Marrow Transplantation
 Blood

Honors and Prizes:

2007	Gold Humanism Honor Society	Mount Sinai Medical School	Academic honor
2007	Alpha Omega Alpha	Mount Sinai Medical School	Academic Honor Society
2008	Irwin Gelernt, MD Graduation Award	Mount Sinai Medical School	Community Service Award

2008	Dr. John J. Bookman Memorial Prize	Mount Sinai Medical School	Award for Demonstration of Scholarship, integrity and compassion in internal medicine
2012	Clinical Research Workshop	AACR/ASCO	Academic honor- invitation to participate in workshop, developing a clinical trial protocol BAand advanced methodology in clinical research design.
2013	Abstract Merit Award	ASCO	Academic Research Award
2014	The Merrill J. E Gorin workshop in cancer therapeutics	Society for Translational Oncology	Academic honor- invitation to participate in workshop, focused on clinical trial design and translational research.
2015	Clinical Research Training Institute	ASH	Academic honor- invitation to participate in workshop, where I developed a clinical trial which will open in the fall of 2019 titled "Pembrolizumab in advanced MPN"
2017	Next Gen Innovators	HemOnc Today	Award recognized academic and research contributions
2019	Resident Teaching Award	MGH	

Report of Funded and Unfunded Projects

Funding Information:

Past

2014	ASCO Young Investigator Award Conquer Cancer Foundation Clinical Investigator \$50,000 The major goal of this project is to conduct a phase II trial using the Hsp90 inhibitor AU922 for myeloproliferative neoplasms
------	--

- 2015 American Cancer Society (ACS) Institutional Research Grant Award
Clinical Investigator
\$30,000
The primary objective of this project is to perform a pre-clinical assessment of PD-1 as a target in myeloproliferative neoplasm.
- 2018- 2020 Pembrolizumab for Advanced Myeloproliferative Neoplasms.
Protocol 17-480
Funding: Merck
Lead PI
Total Direct Costs: \$1,000,000
This is phase II, multicenter study evaluating the use of pembrolizumab in patients with myelofibrosis or accelerated and blast phase MPN Status: Active
Current
- 2020- 2024 American Society of Hematology- Harold Amos Faculty Development Program
Overall PI
\$420,000
The primary objective of this project is to correlate genetic mutations before and after transplant for patients with myelofibrosis with outcomes. This work will involve next generation sequencing as well as single cell profiling. In addition, this work aims to understand the cause of unexplained persistent cytopenias post-transplant in MF patients.
- 2021-2024 Physician and/or Scientist Development Award
Overall PI
\$180,000
The objective of this project is to investigate immune responses to vaccination against COVID-19 in patients with myeloproliferative neoplasms by measuring rates of seroconversion, and T cell responses as well as by mass cytometry.
- 2016- 2021 K-12 Paul Calabresi Award in Clinical Oncology
Harvard
Overall PI- Timothy Graubert
Grant number: CA087723
Clinical Investigator
\$100,000
The primary objective of this project is to assess the role of the PD-1/L1 pathway in patients with myeloproliferative neoplasms using patient samples as part of routine care and as part of clinical trial with Pembrolizumab, a PD-1 checkpoint inhibitor.
- 2017- study completion Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission.
Protocol 17-273.
Funding: Incyte
Lead PI
Total direct costs: \$1,425,000
This is a phase II, investigator initiated study, investigating the safety and efficacy of ruxolitinib for patients over the age of 60 undergoing a stem cell transplant for AML in first remission. This study will be conducted at MGH, Washington University, Vanderbilt and Ohio State University. Status: Active

2018- study completion A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis.
 Protocol 17-569
 Funding: Incyte
 Lead PI
 Total Direct Costs: \$1,545,000
 This is a phase II study evaluating the use of ruxolitinib before, during and after transplant for patients with myelofibrosis. Status: Active

Report of Local Teaching and Training

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs):

2014-present	Introduction to hematologic malignancies Teaching Conference DFHCC Fellows	Massachusetts General Hospital 1 lecture per year
2014-2020	Monthly leukemia conference Teaching Conference DFHCC Fellows, hematopathology and leukemia staff	Massachusetts General Hospital 2 lectures per year

Clinical Supervisory and Training Responsibilities:

2014-	Inpatient Attending Physician in Leukemia Unit for MGH and DFCI Medical Oncology Residents: Supervision, education and training	Massachusetts General Hospital 5 hr/week
2014-	Outpatient Attending Physician In Ambulatory Clinical Leukemia Unit for DFHCC Medical Oncology first and second year Fellows: Supervision, education and training	Massachusetts General Hospital 3 hr/week
2014-	Hematology and Oncology Resident Continuity Clinic Preceptor for MGH residents	Massachusetts General Hospital 2 hr/week

Other Mentored Trainees and Faculty:

2017-2018	Marcia Garcia-Jimenez, MD. Career Stage: Transitional year between residency and fellowship ASCO Minority Faculty Mentor.
2017-	Orly Leiva, MD Career Stage: Fellow. Initially mentored during his fourth year as a Medical Student at Boston University through the American Society of Hematology Minority Medical Student Awardee Mentor. Mentored him during residency at Brigham and Women's

Hospital, and continue to mentor him as a fellow in cardiology at NYU. We have worked on multiple database driven projects to understand cardiovascular outcomes in patients with MPN.

- 2017-2021 Vinayak Vankataraman, MD
Career stage: Met during his junior resident MGH Med/Peds residency *Mentoring role:* During residency we met monthly to discuss career development, follows patients longitudinally in clinic with me. We wrote a case report for publication of presentation of clinical expertise and insight in interesting patient we shared. He is currently a DFHCC fellow and we meet informally to discuss career plans.
- 2017-2019 Kathleen Miller, MD
Career stage: Resident MGH, internal medicine residency. *Mentoring role:* Work on outcome projects in myelofibrosis and provide mentorship on career development. Presented abstract at ASCO 2018, currently writing manuscript on this work
- 2018-2018 Ista Egbeto, BA
Career Stage: Medical Student, Tufts University, 3rd year.
 American Society of Hematology (ASH) Minority Medical Student Awardee Mentor.
 Meet in person to discuss career development and provide her with clinical exposure to patients in clinic.
- 2018-2019 Evan Chen, MD
Career Stage: Fellow, DFHCC
Role: Hematology and Oncology Resident Continuity Clinic Preceptor
 Successfully applied for an ASH Scholar award to characterize outcomes of MDS and MPN patients spliceosome mutations.
- 2018- Chi-Joan How, MD
Career Stage: Instructor, BWH
Role: Mentored Dr. How throughout her hematology/oncology fellowship at DFHCC. Have worked together on the development of clinical trials for patients with MPNs, have published multiple manuscripts on MPN treatment including outcomes for MPN patients during pregnancy. Helped Dr. How transition to her first faculty position.

Formal Teaching of Peers (e.g., CME and other continuing education courses):

No presentations below were sponsored by outside entities

- | | | |
|----------------|--|------------|
| 2/2016 | Updates in Myeloproliferative Neoplasms
Harvard Medical School CME course | Boston, MA |
| 3/2021, 4/2021 | Capstone Internal Medicine Track: Oncologic
Emergencies lecture for 4 th year medical students | Boston, MA |
| 2020-present | Research Roundtable, 5 hours/year | Boston, MA |

Local Invited Presentations:

No presentations below were sponsored by outside entities

3/2015, 3/2016	Controversial Cases in Hematologic Malignancies, "Management of Myeloproliferative Neoplasms" MGH hematologic malignancies conference, Invited Presenter. Boston, MA.
6/2016	Updates on Myelofibrosis, Massachusetts General Hospital, Leukemia Conference. Department of Medicine, Hematology/Oncology Division, Massachusetts General Hospital
11/2016	"Creation of a Leukemia Service Overview", Jiahui Hospital Group, Invited Presenter, MGH, Boston, MA.
1/2017	"Updates in Myeloproliferative Neoplasms" Norman Knight Nursing Center for Blood and Marrow Transplantation, Invited Speaker. MGH, Boston, MA.
10/2017	Updates and Management of CML, Massachusetts General Hospital, Leukemia Conference
10/2018, 10/2019	Updates and Management of Myelofibrosis, Massachusetts General Hospital, Leukemia Conference
02/2019	MGH Resident Report- Expert Discussant on CMML Case and Oncology Didactic on FN/Infectious Emergencies in Oncology Patients. Department of Medicine, Hematology/Oncology Division, Massachusetts General Hospital
4/2019	"Ruxolitinib and Transplantation for Myelofibrosis," Invited presenter. Leukemia and Lymphoma Research Meeting, Dana Farber Harvard Cancer Center.
11/2019	"Choosing and Switching TKIs in CML," Invited presenter, Leukemia Lymphoma Society Chronic Leukemia Rounds, Tufts University.
9/2020, 8/2021	MDS/MPN Teaching Seminar for first year Hematology/Oncology Fellows, Massachusetts General Hospital.
11/2020 2/2021	Resident Report, invited presenter, Faulkner Hospital/Brigham and Women's Hospital.
5/2021	"Mastocytosis and related conditions." Invited Speaker, Allergy and Immunology Grand Rounds, Massachusetts General Hospital

Report of Regional, National and International Invited Teaching and Presentations

Those presentations below sponsored by outside entities are so noted and the sponsor is identified

Regional

1/2014	"The emerging role of Hsp90 Inhibitors in MPN", University of Massachusetts Memorial Medical Center, Grand Rounds. Worcester, MA.
--------	---

- 9/2015 Aplastic Anemia & Myelodysplastic Disease (AA&MDS) Conference, “MDS: Current Thinking on disease Diagnosis and Treatment.” Invited Presenter, Boston, MA
- 3/2016 MPN Advocacy and Education International Conference, “Myeloproliferative Neoplasms- Diagnosis and Treatment. Unscrambling the acronym salad.” Invited Presenter. Boston, MA
- 7/2016 “Updates on MPN’s“ Incyte Scientific Affairs Group, Invited Presenter, Boston, MA.
- 11/2017 Tumor Board Discussion on MPN’s, Invited Speaker, Lowell General Hospital, Lowell, MA.
- 7/2018 Tumor Board Discussion on MPN’s, Invited Speaker, Emerson Cancer Center, Westford, MA.
- 9/2018 “Myelofibrosis: Update on Diagnosis, Management and Research Development “Invited Speaker, Boston University Medical Center, Cancer Center Grand Rounds, Boston, MA
- 10/2018 “Immunotherapy for Myeloproliferative Neoplasms” Novel Therapies in Hematologic Malignancies Symposium, Invited Speaker, Brown University, Rhode Island
- 9/2019 MPN Advocacy and Education International Conference, Invited Presenter, Boston, MA.
10/2019 “Keeping up with evolving treatment landscapes in clinical pathways: Strategies In CML.” Oncology Clinical Pathways Congress, Invited Presenter, Boston, MA
- 1/2020 Clinical Care Options, “Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice.” Invited Presenter, Hyannis, MA
- 9/2021 “Myeloproliferative neoplasms: updates on management and research developments” Invited speaker, Lowell General Cancer Center Grand Rounds, Lowell, MA.
- 9/31/2021 “Improving allogeneic stem cell transplant outcomes in patients with myelofibrosis.” MGH Grand Rounds, Invited Presenter, Boston, MA
- 7/2022 “Management of CML patients” MGH Novartis Preceptorship, Invited Presenter, Boston, MA

National

Those presentations below sponsored by outside entities are so noted and the sponsor is identified

- 2/2014 “Do Patients With High Risk or Relapsed Core Binding Factor Acute Myeloid Leukemia Benefit from Salvage Allogeneic Stem Cell Transplantation? American Society of Blood and Marrow Transplantation, Oral Abstract, 2014. (*Shared last authorship). Gaylord, TX.
- 9/2015 Progress in the treatment of Polycythemia Vera, CancerCare National Teleconference, Invited Presenter, Online Presentation

- 7/2018 Voices of MPN sponsored documentary series, "Gravity." MPN expert discussant, Marriott Hotel, Portsmouth, NH. Sponsored by Incyte Corporation.
- 9/2018 ASH Meeting on Hematologic Malignancies, "How I treat CML when initial TKI therapy has not been successful" Invited Presenter, Chicago, IL
- 9/2018 Myeloproliferative Neoplasm Advocacy and Education International Conference, "Women in MPN" Invited Presenter, Chicago, IL
- 3/2020 MPN Advocacy and Education International Conference, "Physician Summit" Invited Presenter, San Francisco, CA
- 4/2020 Clinical Care Options, "Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice." Invited Presenter, Brooklyn, NY
- 9/2020 "A Young Man with Polycythemia Vera and Fatigue," Society of Hematology and Oncology, Invited Presenter, Houston, TX.
- 9/2020 "Thrombosis in PV: How To Predict and How to Reduce the Risk," Society of Hematology and Oncology, Invited Presenter, Houston, TX.
- 10/2020 ASH Hematology Review Series. "Eosinophilia", Invited presenter and moderator for live Q&A session.
- 10/2021 Virtual Hematologic Malignancies Congress NCCN. "Post-MPN Acute Leukemia," Invited presenter.
- 12/2021 American Society of Hematology Education session. "Advanced Phase CML: Room for Improvement" Invited presenter, Atlanta, GA.
- 12/2021 American Society of Hematology, Oral session. "Ruxolitinib before, during and after transplantation for patients with primary or secondary myelofibrosis" invited presenter, Atlanta, GA.
- 4/2022 NCCN Patient Webinar, invited presenter "MPNs: Know what your doctors know."
- 9/2022 ASH Meeting on Hematologic Malignancies "How I Use Interferons in Polycythemia Vera", Chicago, IL

International

Those presentations below sponsored by outside entities are so noted and the sponsor is identified

- 9/2018 How I treat Hematologic Malignancies 2018, "How I treat CML when initial TKI therapy has not been successful" Invited Presenter, Brussels, Belgium. Sponsored by Springer Healthcare and Janssen Belgium.
- 3/4/2021 "What are the drugs or combinations that may threaten the supremacy of ruxolitinib in primary myelofibrosis?" Invited Presenter, IV Symposium in Hematologic Oncologic Disorders, Sao Paulo, Brazil

Report of Clinical Activities and Innovations

Current Licensure and Certification:

2011	Board Certification in Internal Medicine
2012	Massachusetts Medical License
2014	Board Certification in Hematology
2014	Board Certification in Medical Oncology
2020	Rhode Island Medical License
2020	New Hampshire Medical License
2020	Maine Medical License

Practice Activities:

2014-	Inpatient Service Attending Physician, Leukemia	Massachusetts General Hospital Cancer Center	8 weeks inpatient service per year
2014-	Ambulatory Service, Leukemia Outpatient Clinic	Massachusetts General Hospital Cancer Center	4 half day clinic sessions per week
2016-	Ambulatory Service, Leukemia Outpatient Clinic	MGH Cancer Center at Waltham, MA	4 sessions per month

Clinical Innovations:

MPN research program MGH 2014-

I have established a multidisciplinary clinical and research program for the care of patients with MPN at MGH. From a clinical perspective, I actively care for over 400 patients with MPN. I have trained the practice RNs, NPs and research staff on how to care for patients with MPN. All patients seen as part of the MPN clinic are part of the MGH MPN database and are offered the opportunity to participate in research. Most patients participate in our tissue bank, and samples are used actively by researchers across the DFHCC.

Report of Education of Patients and Service to the Community

Activities

8/2020	Latin American press briefing interview including interviews with La Jornada, Web De la Salud, Mi estilo es salud, Shanafilms- Interviewed by Latin American Press outlets on Leukemia care at MGH and in general.
9/9/2020	Radio Interview with ¡Qué tal Fernanda!

National Mexican radio show with over 5 million listeners. I invited to speak about leukemia care in Spanish.

9/23/2020

“Watching and Waiting: Decision Making with MPNs” Invited speaker, Patient Power Webinar.

11/2020

Latinas Know Your Rights: COVID Discussion, invited speaker for LKYR to discuss COVID with Spanish speaking participants.

7/21/2021,
12/8/2021,
5/18/2022

“Answers Now: What do we know about MPN progression?” Invited speaker, Patient Power Webinar

9/29/2021

“Polycythemia Vera” CURE on MPN Summit Presentation, Invited speaker

Recognition:

2017 Awardee, MPN Heroes Recognition Program Cure Magazine

Report of Scholarship

Peer-Reviewed Scholarship in print or other media:

Research Investigations:

1. Herrera, A. *, **Soriano, G.***, Bellizzi, A., Hornick, J., Ho, V., Ballen, K., Baden, L., Corey, C., Antin, J., Soiffer, R., Marty, F. Cord Colitis Syndrome in Cord-Blood Stem-Cell Transplantation. Brigham and Women’s Hospital, Dana Farber Cancer Institute. New England Journal of Medicine, September 1, 2011; 365 (9):815-824. (*Shared first authorship).
2. Bhatt, A., Freeman, S., Herrera, A., Sekhar Pedamallu, C, Gevers, D., Duke, F., Jung, J., Michaud, M., Walker, B., Young, S., Earl, A., Kostic, A., Ojesina, A, Hasserjian, R., Ballen, K., Chen, Y., **Hobbs, GS.**, Antin, J., Soiffer, R., Baden, L., Garrett, W., Hornick, J., Marty, F., and Meyerson, M. Sequence-Based Discovery of Bradyrhizobium Enterica in Cord Colitis Syndrome. Brigham and Women’s Hospital, Dana Farber Cancer Institute. New England Journal of Medicine, August 8, 2013; 369(6):517-28.
3. **Hobbs, GS***, Hamdi*, A., Hilden, P., Goldberg, J, Poon, M., Ledesma, M., Devlin, S., Rondon, G., Papadopoulos, E., Jakubowski, A., O’Reilly, R., Champlin, R., Giralt, S., Perales, M*, Kebriaei, P*. Outcomes in Patients with Acute Lymphoblastic Leukemia in First or Second Complete Remission Receiving Ex-Vivo T-Cell Depleted or Unmodified Allografts: Comparison of Results at Two Institutions. Bone Marrow Transplant, 2015 Apr;50(4):493-8.

4. **Hobbs, G.S.**, Landrum, M.B., Arora, N.K., Ganz, P.A., van Ryn, M., Weeks, J.C., Mack, J.M., Keating, N.L. The Role of Families in Decisions Regarding Cancer Treatments. *Cancer*, 2015 Apr 1;121(7):1079-87.
5. **Hobbs, GS**,* Kaur, N*, Hilden, P., Ponce, D., Cho, C., Castro-Malaspina, H., Giral, S., Goldberg, JD., Jakubowski, A., Papadopoulos, E., Sauter, C., Koehne, G., Delvin, S., Barker, J., Perales, MA., Novel Reduced Intensity Conditioning Regimen for Patients with High Risk Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation. *Bone Marrow Transplant*, 2016 Jul;51(7):1010-2.
6. Brunner AM*, **Hobbs G***, Jalbut MM, Neuberg DS, Fathi AT. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. *Leuk Lymphoma*. 2016 May;57(5):1197-1200.
7. El-Jawahri A, Keenan T, Abel GA, Steensma DP, LeBlanc TW, Chen YB, **Hobbs G**, Traeger L, Fathi AT, DeAngelo DJ, Wadleigh M, Ballen KK, Amrein PC, Stone RM, Temel JS. Potentially avoidable hospital admissions in older patients with acute myeloid leukemia in the USA: A retrospective analysis. *Lancet Haematol*, 2016;3(6):e276-83.
8. Fathi AT, Wander SA, Blonquist TM, Brunner AM, Amrein PC, Supko J, Hermance NM, Manning AL, Sadrzadeh H, Ballen KK, Attar EC, Graubert TA, **Hobbs G**, Joseph C, Perry AM, Burke M, Silver R, Foster J, Bergeron M, Ramos AY, Som TT, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Chen YB. Phase I study of the aurora A Kinase Inhibitor Alisertib with Induction Chemotherapy in Patients with Acute Myeloid Leukemia. *Haematologica*. April 2017;102(4):719-727.
9. Perry A, Brunner AM, Zou T, McGregor KL, Amrein PC, **Hobbs GS**, Ballen KK, Neuberg DS, Fathi AT. Association between insurance status at Diagnosis and Overall Survival in Chronic Myeloid Leukemia; A population-based study. *Cancer*. 2017 Jul;123(13):2561-2569.
10. Mesa RA, Jaimeson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podolstev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. NCCN Guidelines Insights: Myeloproliferative neoplasms, Version 2.2018. *JNCCN* 2017 Oct;15(10):1193-1207.
11. Jalbut MM, Brunner AM, Amrein PC, Ballen KK, **Hobbs GS**, Perry AM, Joseph CP, Fathi AT. Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. *Leuk Lymphoma*. 2018 Apr;59(4):988-991.
12. DeAngelo DJ, Brunner AM, Werner L, Avigan D, Fathi AT, Sperling AS, Washington A, Stroopinsky D, Rosenblatt J, McMasters M, Luptakova K, Wadleigh M, Steensma DP, **Hobbs GS**, Attar EC, Amrein PC, Ebert BL, Stone RM, Ballen KK. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. *Am J Hematol*. 2018 Feb;93(2):254-261.
13. **Hobbs GS**, Hanasoge Somasundara AV, Kleppe M, Litvin R, Arcila M, Ahn J, McKenney AS, Knapp K, Ptashkin R, Weinstein H, Heinemann MH, Francis J, Chanel S, Berman E, Mauro M, Tallman MS, Heaney ML, Levine RL, Rampal. Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. *RK.Haematologica*. 2018 Jan;103(1):e5-e9

14. Lancman G, Brunner AB, Hoffman, R, Masarenhas J, **Hobbs, GS**. Outcomes and predictors of survival in blast phase myeloproliferative neoplasms. *Leuk Res*. 2018 May 21;70:49-55

15. Fathi AT, **Hobbs G**, Dey BR, Chen YB, Lenalidomide combined with mismatched microtransplantation for acute myeloid leukemia, *Am J Hematol*. 2018 Oct;93(10):E331-E333.

16. El-Jawahri A, Nelson-Lowe M, VanDusen H, Traeger L, Abel GA, Greer JA, Fathi A, Steensma DP, LeBlanc TW, Li Z, DeAngelo D, Wadleigh M, **Hobbs G**, Foster J, Brunner A, Amrein P, Stone RM, Temel JS., Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia , *Oncologist*. 2018 Aug 23; 2018-0317

17. Boiocchi L, Hasserjian RP, Pozdnyakova O, Wong WJ, Lenners JK, Le LP, Dias-Santagata D, Iafrate AJ, **Hobbs GS**, Nardi V. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. *Human Pathology*. 2018 Dec 27; Vol. 86; 1-11.

18. Gotlib J, Gerts AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundablou K, **Hobbs G**, Jaimeson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardani A, Podolstev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H. *JNCCN* 2017 Dec;16(12):1500-1537.

19. Chen EC, Werner L, **Hobbs GS**, Narayan R, Amrein PC, Fathi AT, Brunner AM. Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. *Leuk Lymphoma* 2019 May 23: 1-5.

20. El-Jawahri A, Abel GA, Traeger L, Waldman L, Markovitz N, VanDusen H, Fathi A, Steensma DP, LeBlanc TW, Horick NK, DeAngelo DJ, Wadleigh M, **Hobbs G**, Foster J, Brunner AM, Amrein P, Stone RM, temel JS, Greer JA. Quality of life and mood of older patients with acute myeloid leukemia receiving intensive and non-intensive chemotherapy. *Leukemia*, 2019 Mar 28.

21. Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, **Hobbs G**, Jaimeson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardani A, Podolstev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H. Systemic Mastocytosis Version 2.2019, version 1.2019, *J NCCN* 2018 Dec, 16(12):1500-1537.

22. Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, Attar E, **Hobbs GS**, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, Adamia S, Borger DR, Iafrate A, Graubert TA, Stone RM, Fathi AT. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. *Cancer*, 2019 Feb 15;125(4):541-549.

23. El-Jawahri A, Nelson-Lowe M, VanDusen H, Traeger L, Abel GA, Greer JA, Fathi A, Steensma DP, LeBlanc TW, Li Z, DeAngelo D, Wadleigh M, **Hobbs G**, Foster J, Brunner A, Amrein P, Stone RM, Temel JS. Patient-clinician discordance in perceptions of treatment risks and benefits in older patients with acute myeloid leukemia. *Oncologist*, 2019 Feb;24(2):247-254.

24. Slavin SD, Fenech A, Jankowski AL, Abel GA, Brunner AM, Steensma DP, Fathi AT, DeAngelo DJ, Wadleigh M, **Hobbs GS**, Amrein PC, Stone RM, Temel JS, El-Jawahri A. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. *Cancer* 2019.
25. Signorelli J, Luk S, Tavares E, **Hobbs GS**. Antiemetic prophylaxis for induction chemotherapy in patients with acute myeloid leukemia. *Journal of Pain and Symptom Management*, 2020
26. Strohbehn S, Seethapathy H, Rusibamayila N, Strohbehn I, Lee M, **Hobbs GS**, Keyzner A, Jhaveri KD, Sise ME. Acute Kidney Injury after Ruxolitinib: Common complication, uncommon cause. *American Journal of Hematology*, Apr 2, 2020.
27. Jan M, Grinshpun DE, Villalba JA, Dal Cin P, Sykes DB, Iafrate J, Ebert L, **Hobbs GS**, Nardi V. "A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. *Blood Advances* (2020) 4 (3); 445-448.
28. **Hobbs, GS**, Mascarenhas J. Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera, Lymphoma Myeloma and Leukemia, May 26, 2020.
29. Zeidan AM, Boddur PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, **Hobbs GS**, Stein E, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, König H, Komrokji R, Deininger M, Xicoy Cirici B, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang E, Tallman MS, Stone, RM and Mascarenhas J. Special Considerations in the Management of Adult Patients with Acute Leukaemias and Myeloid Neoplasms in the COVID-19 Era: Recommendations by an International Expert Panel. *Lancet Hematology*, 2020.
30. Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, **Hobbs G**, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Lubner K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Diaz MA, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura BL, Mesa R, Saber W. Survival following allogeneic transplantation in myelofibrosis, *Blood Advances* (2020) 4 (9): 1965–1973
31. Nardi V, Ku N, Frigault MJ, Dubuc AM, Tsai HK, Amrein PC, Hobbs GS, Brunner AM, Narayan R, Burke ME, Foster J, Dal Cin P, Maus MV, Fathi AT, Hock H. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. *Blood Advances*, 2020 Jan 14;4:14(1):106-111.
32. Kasbekar M, Nardi V, Dal Cin P, Brunner AM, Burke M, Chen Y, Connolly C, Fathi A, Foster J, Macrae M, McAfee S, McGregor K, Narayan R, Ramos AY, Som TT, Vartanian M, Friedman RS, Benhadji KA, and **Hobbs GS**. Targeted FGFR inhibition results in a durable remission in a FGFR1 driven myeloid neoplasm with eosinophilia. *Blood Advances*, Vol 4 (13), July, 2020.
33. Venkataraman V, Casey KS, Onozato M, Cin PD, Nardi V, Amrein, PC, Bergeron MK, Brunner AM, Fathi AT, Foster JE, Moran J, Graubert TA, Hock H, Hunnewell C, Frigault MJ, McAfee S,

Hobbs GS. Molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. *Leukemia*, July 2020.

34. Strohbehn S, Seethapathy H, Rusibamayila N, Strohbehn I, Lee M, **Hobbs G**, Keyzner A, Jhaveri KD, Sise ME. Acute kidney injury after ruxolitinib: common complication, uncommon cause. *Am J Hematol.* 2020 Jul;95(7):E181-E183.
35. Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jaimeson C, Kuykendall AT, McMahon B, Mohan SR, Oehler V, Oh S, Pardanani A, Podolstev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar H, Myeloid/Lymphoid Neoplasms with Eosinophilia and TK fusion genes version 3.2021. *JNCCN.* 2020 Sep; 18(9):1248-1269.
36. How CJ, Leiva O, Bogue T, Fell G, Bustoros M, Connel N, Connors J, Ghobrial I, Higgins N, Jessop N, Kutter K, Story J, Mulally A, Nardi V, Neubert D, Styles R, Zwicker J, Fogerty A*, **Hobbs GS***, Outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. *Leukemia Research*, 2020.
37. Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, Deangelo DJ, Gotlib J, Hobbs G, Maness L, Mead M, Metheny L, Mohan S, Moore JO, Vaqvi K, Oehler V, Pallera AM, Patnaik M, Pratz K, Pusic I, Rose MG, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thomson J, Yang DT, Gregory KM, Sundar H. *NCCN Guidelines Insights: Myeloproliferative neoplasms, Version 2.2021. JNCCN* 2020 Oct;1(10):1385-1415.
38. Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, **Hobbs GS**, Quaas A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, Duda DG. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. *J Immunother Cancer.* 2020 Nov;9(2):e001435.
39. Reynolds KL, Klempner SJ, Parikh A, Hochberg EP, Michaelson MD, Mooraidian MJ, Lee RJ, Soumerai TE, **Hobbs G**, Piotrowska Z, Sykes DB, Farago AF, Bardia A, Rosovsky RP, Ryan DP. The art of oncology: COVID-19 Era. *Oncologist.* 2020 Nov;25(11):997-1000g.
40. Amonoo HL, LeBlanc TW, Kavanaugh AR, Webb JA, Traeger LN, Jagielo AD, Vaughn DM, Elyze M, Longley RM, Fathi AT, Hobbs GS, Brunner AM, O'Connor NR, Luger SM, Gustin JL, Bhatnagar B, Horick NK, El-Jawahri A. Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia. *Cancer.* 2021 Jul 15;127(14):2500-2506.
41. El-Jawahri A, LeBlanc TW, Kavanaugh A, Webb JA, Jackson VA, Campbell TC, O'Connor N, Luger SM, Gafford E, Gustin J, Bhatnagar B, Walker AR, Fathi AT, Brunner AM, **Hobbs GS**, Nicholson S, Davis D, Addis H, Vaughn D, Horick N, Greer JA, Temel JS. Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: A randomized clinical trial. *JAMA Oncol.* 2021 Feb 1;7(2):238-245.
42. Leiva O, Baker O, Jenkins A, Brunner AM, Al-Samkari H, Leaf RK, Rosovsky RP, Fathi AT, Witzman J, Bornikova L, Nardi V, **Hobbs GS**. Association of Thrombosis with Hypereosinophilic syndrome in patients with genetic alterations. *JAMA Netw Open*, 2021 Aug 2;4(8):e2119812
43. Egeren DV, Escabi J, Nguyen M, Liu S, Reilly CR, Patel S, Kamaz B, Kalyva M, Deangelo DJ, Galinsky I, Winer ER, Luskin MR, Stone RJ, Garcia J, Hobbs GS, Camargo FD, Michor F,

Mullally A, Cortes-Ciriano I, Hormoz S. Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms, *Cell Stem Cell*. 2021 Mar 4;28(3): 514-523.

44. Hobbs GS, Cimen Bozkus C, Moshier EL, Dougherty M, Bar-Natan M, Sandy L, Johnson K, Foster J, Som T, Macrae M, Marble H, Salama M, El Jamal S, Zubizarreta N, Wadleigh M, Stone RM, Bhardwaj N, Iancu-Rubin C, Mascarenhas J, PD-1 inhibition in advanced myeloproliferative neoplasms, *Blood Advances*. 2021 Sep 28
45. Naranbhai V, Pernat CA, Gavralidis A, St Denis KJ, Lam EC, Spring LM, Isakoff SJ, Farmer JR, Zubiri L, **Hobbs GS**, How J, Brunner AM, Fathi AT, Peterson JL, Sakhi M, Hambelton G, Denault EN, Mortensen LJ, Perriello LA, Bruno MN, Bertaux BY, Lawless AR, Jackson MA, Niehoff E, Barabell C, Nambu CN, Nakajima E, Reinicke T, Bowes C, Berrios-Mairena CJ, Ofoman O, Kirkpatrick GE, Thierauf JC, Reynolds K, Willers H, Beltran WG, Dighe AS, Saff R, Blumenthal K, Sullivan RJ, Chen YB, Kim A, Bardia A, Balazs AB, Iafrate AJ, Gainor JF. Immunogenicity and reactogenicity of SARS-CoV-2 Vaccines in patients with Cancer: The CANVAX cohort study, *J Clin Oncol*. 2021 Nov 9.
46. How J, Story C, Ren S, Neuberg D, Rosovsky RP, Hobbs GS, Connors JM. Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients, *Blood Cancer J*. 2021 Nov 5;11(11);176.
47. Anandappa AJ, Hobbs GS, Dey BR, El-Jawahri A, Frigault MJ, McAfee SL, O'Donnell PV, Spitzer TR, Chen YB, DeFilipp Z. Hypoxemic respiratory failure following ruxolitinib discontinuation in allogeneic hematopoietic cell transplantation recipients. *Oncologist*. 2021 Nov;26(11).
48. Signorelli J, Fathi AT, **Hobbs GS**. Dasatinib-Induced Gynecomastia in 2 Patients with Chronic Myeloid Leukemia: Case Reports and Review of the Literature. *JHOP*, February 2022, Vol 12 (1).
49. How J, Gallagher K, Liu Y, Katsis K, Elder EL, Larson RC, Leick MB, Neuberg D, Maus MV, Hobbs GS. Antibody and T-Cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. *Leukemia* 2022, Feb 25; 1-4.

*Shared first authorship.

Other, Peer-Reviewed:

1. Heaney M, **Soriano G**, Acute Myeloid Leukemia Following a Myeloproliferative Neoplasm: Clinical Characteristics, Genetic Features and Effects of Therapy. *Current Hematologic Malignancy Reports*. 2013 Jun;8(2):116-22.
2. **Hobbs, GS.**, Rampal, RK. Clinical and Molecular Genetic Characterization of Myelofibrosis. *Current Opinion in Hematology*, March 2015, 22(2); 117-183.
3. **Hobbs, GS**, Perales, MA. Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients. *Journal of Clinical Medicine*, 2015 4(3), 488-503.

4. Stein, BL, Oh, S., Berenzon, D, **Hobbs, GS**, Kremyanskaya, M, Rampal, RK., Abboud, C., Adler, K, Heaney, M, Jabbour, EJ., Komrokji, RS, Moliterno, AR, Ritchie, EK, Rice, R, Mascarenhas, J, Hoffman, R. Polycythemia Vera: An Appraisal of the Biology and Management 10 years after the Discovery of JAK2V617F. *J Clin Oncol.* 2015 Nov 20;33(33):3953-60.
5. Pallerla, A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, **Hobbs GS**, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. *J National Canc Netw.* 2016 Dec; 14(12): 1505-1512.
6. Mesa, R., Jamieson, C., Bhatia, R., Deninger, MW., Gerds AT., Gotlib, J., Gundabolu, K. **Hobbs, GS.**, Klisovic, RB., Kropf, P/, Mohan, SR., Oh, S., Padron, E., Podolstev, N., Rampal, R., Rein, LA., Scott, B., Snyder, DS., Stein, BL., Verstovsek, M., Wadleigh, M., Wang, ES., Bergman, MA., Gregory, KM., Sundar, H. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*, 2016; Dec:14(12):1572-1611.
7. Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, **Hobbs G**, McMahan B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podolstev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. *J Natl Compr Canc Netw.* 2017 Oct;15(10):1193-1207.
8. Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, **Hobbs G**, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallerla A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H., Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2018 Sep;16(9):1108-1135
9. Sadigh S, Hasserjian RP, **Hobbs GS**. Distinguishing atypical CML from other Philadelphia negative chronic myeloproliferative neoplasms. Current opinion in hematology, in press.

Non-peer reviewed scholarship in print or other media:

Reviews, chapters, monographs and editorials

1. **Soriano G**, Heaney M ,Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications..*Curr Opin Hematol.* 2013 Mar;20(2):169-75. Review.
2. Drlon AE, Postow MA. Pocket oncology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014. (**Hobbs G**, author on section on Coagulation studies), 2014
3. **Hobbs, GS**, Mesa, R. New Drugs for Myelofibrosis. *Expert Opinion on Orphan Drugs.* April, 2016, 4(5); 521-529.
4. **Hobbs GS**, Rozelle S, Mullally A. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. *Hematol Oncol Clin North Am.* 2017Aug;31(4):613-626. Epub 2017 May 17.

5. Kennedy JA, **Hobbs, GS**. Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making. *Curr Hematol Malig Rep*, 2018 April: 1-10. Review.
6. Kennedy JA, Luk SO, **Hobbs GS**. Drugs Targeting the ABL and JAK Kinases, In Chabner, BA, *Cancer Chemotherapy, Immunotherapy and Biotherapy*, 6th edition, Wolters Kluwer 2018.
7. How CJ, **Hobbs GS**, Mullally AM. Mutant calreticulin in myeloproliferative neoplasms. *Blood* (2019) 134 (25): 2242-2248.
8. How CJ, **Hobbs GS**. A practical guide for using myelofibrosis prognostic models in the clinic. *JNCCN*, accepted for publication 9/2020.
9. How CJ, **Hobbs GS**. Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature. *Cancers*, 2021.
10. Javidi-Sharifi N, Hobbs GS. Future directions in chronic phase CML treatment. *Curr Hematol Malig Rep*. 2021 Dec;16(6):500-508.
11. How J, Hobbs GS. Management issues and controversies in low-risk patients with essential thrombocythemia and polycythemia vera. *Curr Hematol Malig Rep*. 2021 Oct;16(5):473-482

Letters to the Editor

1. Herrera, A., **Soriano, G.**, Marty, F. Author Reply- Cord Colitis Syndrome in cord-Blood Stem-Cell Transplantation. Brigham and Women's Hospital, Dana Farber Cancer Institute. *New England Journal of Medicine*, December 15, 2011; 365:2338-2338.
2. **Soriano, G.**, Perales, M., Adenovirus Viremia and Infection After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplant: Should We Institute a Routine Screening Program? (Editorial) *Clinical Infectious Diseases*, September 12, 2012

Clinical Guidelines and Reports:

1. **Hobbs G**. Chronic Myeloid Leukemia. *ACP Smart Medicine*. <http://smartmedicine.acponline.org/content.aspx?gbosId=266>. Updated November 16, 2015.

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings:

1. Brunner AM, Blonquist TM, McMasters M, **Hobbs GS**, McAfee SL, Rosenblatt J, Amrein PC, El-Jawahri A, Connolly C, Ramos A, Mikami K, Logan E, Dey BR, Spitzer T, Avigan DE, Fathi AT, Chen Y, and Ballen KK. Phase I Study of Bortezomib Combined with Lenalidomide for Relapsed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Following Hematopoietic Cell Transplantation. Poster presentation at: American Society of Hematology 2017 Annual Meeting, Atlanta, GA. December 2017.
2. El-Jawahri A, Abel GA, Greer J, Fathi AT, Steensma DP, LeBlanc TW, DeAngelo DJ, Wadleigh M, **Hobbs GS**, Foster J, Brunner AM, Amrein PC, Stone RM, and Temel JS. Perceptions of Prognosis and Treatment Risk in Older Patients with Acute Myeloid Leukemia. Oral presentation at: American Society of Hematology 2017 Annual Meeting, Atlanta, GA. December 2017.

3. Jalbut MM, Chen EC, **Hobbs GS**, Perry AM, Werner L, Amrein PC, Fathi AT, and Brunner AM. The Impact of Antimicrobial Prophylaxis during Induction Chemotherapy for Acute Myeloid Leukemia in the Current Era. Poster presentation at: American Society of Hematology 2017 Annual Meeting, Atlanta, GA. December 2017.
4. Perry AM, Chen EC, Jalbut MM, Werner L, **Hobbs GS**, Amrein PC, Fathi AT, and Brunner AM. Increased Incidence of Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia Among Adults of Hispanic Ethnicity: A Population Based Study. Poster presentation at: American Society of Hematology 2017 Annual Meeting, Atlanta, GA. December 2017.
5. **Hobbs GS**, Brunner AM, Graubert TA, Benes CH, Duda GD, and Chen Y. Preclinical Rationale for the Use of Regorafenib in Myeloid Malignancies. Poster presentation at: American Society of Hematology 2017 Annual Meeting, Atlanta, GA. December 2017.
6. Miller, K. Ho, V. Li, S., Chen, YA., **Hobbs, GS**. The effect of pre-transplant JAK1/2 inhibitors on outcomes of myelofibrosis patients who receive allogeneic stem cell transplant. Poster presentation at: American Society of Clinical Oncology 2018 Annual Meeting, Chicago, IL. June 2018.
7. Boiocchi, L, Pozdnyakova, O, Wong, W, Sohani, A, Hasserjian, R, **Hobbs, G**, Nardi, V, Molecular and Clinico-Pathological Features of SF3B1-Mutated Myeloproliferative Neoplasms. Poster Presentation at: The United States and Canadian Academy of Pathology Annual Meeting 2018
8. Villalba, J, **Hobbs, G**, Sykes, D, Cin Dal, P, Iafrate, J, Hasserjian, R, Nardi, V, A Novel Imatinib mesylate-sensitive cryptic G3BP1-PDGFRB fusion in myeloid neoplasm with eosinophilia. Abstract at: The United States and Canadian Academy of Pathology Annual Meeting 2019
9. Dagny M. Vaughn, MS, P. Connor Johnson, MD, Annemarie D. Jagielo, BA, Matthew J. Reynolds, B, Alison R. Kavanaugh, NP, Jason A. Webb, MD, Amir T. Fathi, M.D., **Gabriela S. Hobbs**, MD, Andrew M. Brunner, MD, Nina R. O'Connor, MD, Selina M. Luger, MD, FRCPC, Bhavana Bhatnagar, DO, Thomas W. LeBlanc, MD, MA, MS and Areej El-Jawahri, MD Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia. Abstract Presentation at Academy of Hematology Annual Meeting 2020
10. Debra Van Egeren, Javier Escabi, Maximilian Nguyen, Shichen Liu, Christopher R. Reilly, MD, Sachin Patel, Baransel Kamaz, MD, Maria Kalyva, Daniel J. DeAngelo, MD, PhD, Ilene Galinsky, Martha Wadleigh, MD, Eric S. Winer, MD, Marlise R Luskin, MD, MS, Richard M. Stone, MD, Jacqueline S. Garcia, MD, **Gabriela S. Hobbs, MD**, Fernando D Camargo, PhD, Franziska Michor, Ph.D., Ann Mullally, MD, Isidro Cortes-Ciriano, Ph.D. and Sahand Hormoz, Ph.D. Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms. Abstract Presentation at American Society of Hematology Annual Meeting 2020
11. Orly Leiva, MD, Olesya Baker, PhD, Andrew M. Brunner, Hanny Al-Samkari, MD, Rebecca Karp Leaf, MD, Rachel P. Rosovsky, MD, MPH, Amir T. Fathi, M.D., James I Weitzman, MD, Larissa Bornikova, MD, Valentina Nardi, MD and **Gabriela S. Hobbs, MD** Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in

Thrombotic Risk. Abstract Presentation at American Society of Hematology Annual Meeting 2020

12. Joan How, MD, Yiwen Liu, Jennifer Lombardi Story, Donna S. Neuberg, ScD, Katya Ravid, PhD, DSc, Wolfgang Jarolim, Brett Charlton and **Gabriela S. Hobbs**, MD Evaluation of a Pan-Lysyl Oxidase Inhibitor, Pxs-5505, in Myelofibrosis: A Phase I, Randomized, Placebo Controlled Double Blind Study in Healthy Adults. Abstract Presentation at American Society of Hematology Annual Meeting 2020
13. Philip C. Amrein, MD, Karen K. Ballen, MD, Kristen E. Stevenson, MS, Traci M. Blonquist, MS, Andrew M. Brunner, **Gabriela S. Hobbs**, MD, Hanno R. Hock, MD, PhD, Steven L. McAfee, MD, Jenna A. Moran, NP, Meghan Bergeron, NP, Julia E. Foster, NP, Christina Bertoli, NP, Kristin McGregor, Molly Macrae, Meghan Burke, Tanya T. Behnan, BS, Tina T. Som, RN, Aura Y. Ramos, RN, Megan K. Vartanian, RN, Jennifer Lombardi Story, Christine Connolly, Timothy A. Graubert, MD, Donna S. Neuberg, ScD and Amir T. Fathi. Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults. Abstract Presentation at American Society of Hematology Annual Meeting 2020
14. Chi-Joan How, MD, Siyang Ren, Jennifer Lombardi Story, Meghan Bergeron, NP, Julia E. Foster, NP, Philip C. Amrein, MD, Andrew M. Brunner, Amir T. Fathi, Hanno R. Hock, MD, PhD, Jenna A. Moran, NP, Rupa Narayan, Donna S. Neuberg, ScD, Aura Y. Ramos, RN, Tina T. Som, RN, Megan Vartanian, RN, Yi-Bin Chen, MD and **Gabriela S. Hobbs**, MD. A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies. Abstract Presentation at American Society of Hematology Annual Meeting 2020
15. Philip C. Amrein, MD, Eyal C. Attar, MD, Geoffrey Fell, Traci M. Blonquist, MS, Andrew M. Brunner, **Gabriela S. Hobbs**, MD, Hanno R. Hock, MD, PhD, Steven L. McAfee, MD, Rupa Narayan, MD, Jenna A. Moran, NP, Meghan Bergeron, NP, Julia E. Foster, NP, Christina Bertoli, NP, Kristin McGregor, Molly Macrae, Meghan Burke, Tanya T. Behnan, BS, Tina T. Som, RN, Aura Y. Ramos, RN, Megan K. Vartanian, RN, Jennifer Lombardi Story, Donna S. Neuberg, ScD and Amir T. Fathi. Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults. Abstract Presentation at American Society of Hematology Annual Meeting 2020
16. **Gabriela S. Hobbs**, MD Cansu Cimen Bozkus, Martha Wadleigh, MD, Lonette Sandy, Mikaela Dougherty, Kathryn Johnson, Gillian Sanchez, Julia E. Foster, NP, Molly Macrae, Tina T. Som, RN, Michal Bar-Natan, MD, Richard M. Stone, MD, Erin Moshier, MS, Camelia Iancu-Rubin, PhD and John Mascarenhas, MD Results of a Phase II Study of PD-1 Inhibition in Advanced Myeloproliferative Neoplasms. Abstract Presentation at American Society of Hematology Annual Meeting 2020
17. Amir T. Fathi, Shuli Li, PhD, Robert J. Soiffer, MD, Mark Levis, MD, PhD, Alice S. Mims, MD, Steven M Devine, MD, Zachariah Defilipp, MD, Areej El-Jawahri, MD, Steven L. McAfee, MD, Thomas R. Spitzer, MD, Matthew J Frigault, MD, MSc, Bimalangshu R. Dey, MD, Philip C. Amrein, MD, **Gabriela S. Hobbs**, MD, Andrew M. Brunner, MD, Hanno R. Hock, MD, PhD, Rupa Narayan, Laura W. Knight, Devon Kelley, AJ S. Bottoms, Jami L. Brown, MS, Candice J. Del Rio, RN, MS, Julie E. Vanderklis, ANP, Colleen Danielson, NP, Meredith L. Saylor, NP, Chrisa L. Hunnewell, Lindsey H. Perry, Jonathan L. Wahl, Elayne Breton, Vincent T. Ho, MD and Yi-Bin Chen, MD. A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation. Abstract Presentation at American Society of Hematology Annual Meeting 2020
18. Hermioni L. Amonoo, MD, Areej El-Jawahri, MD, Thomas W. LeBlanc, MD, MA, MS, Alison R. Kavanaugh, NP2, Jason A. Webb, MD, Lara Traeger, Ph.D., Annemarie D. Jagielo, , Dagny M. Vaughn, MS, Madeleine Elyze, BA, Regina M. Longley, BA, Amir T. Fathi, Gabriela S. Hobbs, MD Andrew M. Brunner, Nina R. O'Connor, MD, Selina M. Luger, MD, FRCPC, Jillian Gustin, MD, Bhavana Bhatnagar, DO and Nora K. Horick, MS. Post-Traumatic Stress

- Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML). Abstract Presentation at American Society of Hematology Annual Meeting 2020
19. **Hobbs GS**, Haesook T. Kim, PhD, AJ S. Bottoms, Michael T. Byrne, DO, Mark A. Schroeder, MD, Roni Tamari, MD, Sarah A Wall, MD, MPH, Zachariah Defilipp, MD, Areej El-Jawahri, MD, Steven McAfee and Yi-Bin Chen, MD, MS, A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Cell transplantation for Patients with Primary or Secondary Myelofibrosis. Abstract Presentation at American Society of Hematology Annual Meeting 2021
 20. How J, Gallagher K, Liu Y, DeMato A, Katsis K, Larson R, Leick M, Neuberg DS, Maus MV, **Hobbs GS**, Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients. Abstract Presentation at American Society of Hematology Annual Meeting 2021
 21. Sadler B, Chorzalska AD, Bonal DM, Haller G, Oakes A, Petersen M, Liu Y, Olszewski A, Reagan JL, Egan PC, Niroula R, Treaba DO, **Hobbs G**, Oh ST, Di Paola J, Baxter JE and Dubielecka P. Whole Genome Sequencing Identifies a Recurrent Mutation in Complement Factor I (CFI) in Primary Myelofibrosis (PMF). Abstract Presentation at American Society of Hematology Annual Meeting 2021
 22. Leiva O, Campia U, Snyder J, Barns B, Rizzo S, Al-Samkari H, Karp Leaf R, Rosovsky R, Goodarzi K, Fathi AT, Goldhaber SZ, Piazza G, and **Hobbs GS**. Increased Risk of Thrombosis in Patients with Myeloproliferative Neoplasms Compared with the General Population Hospitalized with COVID-19. Abstract Presentation at American Society of Hematology Annual Meeting 2021
 23. How CJ, Bachanova P, Pavlovic M, Reeves PM, **Hobbs GS**, MD. Immune Profiling of Responses to Influenza Vaccination in Patients with Myeloproliferative Neoplasms. Abstract Presentation at American Society of Hematology Annual Meeting 2021
 24. How CJ, McIlwaine Story C, Ren S, Neuberg DS, Rosovsky RP, **Hobbs GS** and Connors JM. High Incidence of Bleeding Found with Direct Oral Anticoagulant Use in Myeloproliferative Neoplasm Patients. Abstract Presentation at American Society of Hematology Annual Meeting 2021
 25. Yacoub A, Borate U, Rampal R, Ali H, Wang ES, Gerds AT, **Hobbs GS**, Kremyanskaya M, Winton E, O'Connell C, Goel S, Oh ST, Schiller GJ, Assad A, Erickson-Viitanen S, Zhou F, and Daver N, Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3K δ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF). Abstract Presentation at American Society of Hematology Annual Meeting 2021.
 26. Leiva O, Ren S, Neuberg DS, Bhatt A, Jenkins A, Rosovsky RP, Karp Leaf R, Goodarzi K, and **Hobbs GS**. Pulmonary Hypertension Is Associated with Poor Outcomes in Patients with Myeloproliferative Neoplasms and Cardiovascular Disease. Abstract Presentation at American Society of Hematology Annual Meeting 2021

Narrative Report

As a clinician investigator, my primary goal is to provide comprehensive care for patients with Myeloproliferative Neoplasms (MPNs). I joined the Leukemia Service at Massachusetts General Hospital August of 2014. Over the last 5 years, I established a MPN clinical and research program. My clinical expertise in hematologic cancers is integrated with an active clinical research commitment to provide innovative new therapies for my patients.

To date, my efforts have resulted in the creation of an MPN research program at MGH. These efforts have expanded treatment options for patients at MGH in several ways- Patients have more treatment options through access to MPN specific clinical trials, through participation in translational research

and receive up to date treatment and consultation as part of a therapy team trained in the care of MPNs.

My primary clinical success has been to establish a cohort of patients with MPN from local and regional referrals. I have built a strong referral network that has allowed me to develop a panel that consists of patients with MPN.

The goal of my research is to serve patients through improved understanding of the molecular underpinnings of MPN through strong translational medicine components to my research and through the design and successful completion of innovative clinical trials rooted in strong pre-clinical rationale. I am a clinical research investigator with a growing portfolio as lead PI in national clinical trials. I lead the MPN clinical trials at MGH, all of which include a strong translational component based on collaborations with laboratory investigators. The investigator-initiated studies for which I am the principal investigator include- A phase II, multicenter study, of ruxolitinib before, during and after transplant for patients with myelofibrosis (Protocol 17-569). A phase I study of Regorafenib for patients with advanced myeloid neoplasms (Protocol 16-464). A phase II, multicenter study utilizing ruxolitinib for maintenance after transplant for older patients with AML (Protocol 17-273). A phase II, multicenter study investigating the use of pembrolizumab for myelofibrosis (Protocol 17-480). In addition, I am the site PI for all pharmaceutical sponsored studies in MPN at MGH.

In addition to clinical trials work, I collaborate with several investigators across the Dana Farber Harvard Cancer Center in translational research utilizing samples from the above-mentioned trials. This work includes defining the role of genetic mutations in predicting post- allogeneic hematopoietic stem cell transplantation (SCT) outcomes in myelofibrosis patients utilizing samples from protocol 17-569. In addition, we are investigating the role of immune dysregulation and immunotherapy in patients with MPN. This research utilizes samples of patients collected from my clinic as well as samples from a clinical trial utilizing the checkpoint inhibitor, Pembrolizumab in patients with Myelofibrosis. Through my scientific collaborations, I will also pursue extensive molecular characterization to identify markers of response, resistance and clinical efficacy with additional contributions from my research colleagues at MGH.

In addition to my clinical, administrative and research responsibilities, I am actively committed to the advancement of women and minorities in medicine. I mentor students and residents through the American Society of Hematology Minority Medical Student program and through the ASCO Minority Mentorship Program. Locally, I mentor multiple residents and fellows, I serve as a Heme/Onc continuity clinic preceptor and I am the clerkship director for the hematologic malignancies rotation for DFHCC fellows at MGH.

Ultimately, my goal is to continue to grow the multidisciplinary MPN research group focused on providing high quality care to patients with MPNs, and to develop new treatment options for patients with MPN based on sound pre-clinical rationale, while strengthening collaborations and mentorship across the DFHCC and across the country.